Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined ... compounds in development that leverage different mechanisms of ...

1,2 ENHERTU (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate. Designed using Daiichi Sankyo's proprietary DXd antibody drug conjugate (ADC) technology, ENHERTU consists of a ...

and we look forward to continuing to work with our partners within the drug reimbursement ecosystem to unlock additional mechanisms for accelerating access to more medicines in the future." ...

1,2 ENHERTU (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate. Designed using Daiichi Sankyo's proprietary DXd antibody drug conjugate (ADC) technology, ENHERTU consists of a HER2 ...

--(BUSINESS WIRE)--Datopotamab deruxtecan (Dato-DXd ... of potential new medicines and combinations across diverse mechanisms of action. AstraZeneca is a founding member of the Lung Ambition ...

Enhertu (fam-trastuzumab deruxtecan-nxki*) is a prescription ... This means Enhertu’s mechanism of action involves attacking cancer cells without harming healthy cells. (A drug’s mechanism ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Today I'd like ...

Although a fundamental understanding of the mechanism of action for the antibody-drug conjugate (ADC ... The emerging HER3-directed ADC patritumab deruxtecan (HER3-DXd) has demonstrated potential ...